Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells.
Activating mutations in B-RAF and N-RAS occur in ∼60 and ∼15% of melanomas, respectively. The most common mutation in B-RAF is V600E, which activates B-RAF and the downstream MEK-ERK1/2 pathway. Thus, B-RAF(V600E) is a viable therapeutic target. PLX4720 is a selective inhibitor of mutant B-RAF and its analog, PLX4032, is currently undergoing clinical trials in melanoma. However, the effects of PLX4720 across the genotypic spectrum in melanoma remain unclear. Here, we describe that PLX4720 treatment rapidly induces hyperactivation of the MEK-ERK1/2 pathway in mutant N-RAS melanoma cells. Furthermore, we demonstrate that C-RAF is the major RAF isoform involved in this process. Importantly, PLX4720-induced hyperactivation of the MEK-ERK1/2 pathway promotes resistance to apoptosis in both non-invasive and invasive mutant N-RAS melanoma cells but does not enhance cell cycle properties. These findings underscore the need to genotypically stratify melanoma patients before enrollment on a mutant B-RAF inhibitor trial.
Kaplan
F M
FM
Department of Cancer Biology and Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Shao
Y
Y
Mayberry
M M
MM
Aplin
A E
AE
D017209:Apoptosis / Q000187:drug effects*; D004789:Enzyme Activation; D011905:Genes, ras; D006801:Humans; D007211:Indoles / Q000494:pharmacology*; D008545:Melanoma / Q000201:enzymology / Q000473:pathology*; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors*; D015398:Signal Transduction; D013449:Sulfonamides / Q000494:pharmacology*
D007211:Indoles; C528407:PLX 4720; D013449:Sulfonamides; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf
Nature. 2006 Jan 19;439(7074):358-62
16273091
Oncogene. 1989 Nov;4(11):1363-74
2682463
Pigment Cell Melanoma Res. 2010 Apr;23(2):190-200
20149136
Cancer Res. 2006 Oct 1;66(19):9483-91
17018604
Cancer Res. 2003 Feb 15;63(4):756-9
12591721
Mol Cancer Res. 2009 Apr;7(4):549-56
19372583
J Clin Endocrinol Metab. 2010 Jan;95(1):450-5
19880792
Oncogene. 2008 May 22;27(23):3301-12
18246127
Nature. 2010 Mar 18;464(7287):427-30
20179705
Chem Biol. 1999 Aug;6(8):559-68
10421767
Nature. 2010 Mar 18;464(7287):431-5
20130576
Cancer Res. 2006 Dec 1;66(23):11100-5
17145850
Mol Cell Biol. 2006 Mar;26(6):2262-72
16508002
Oncogene. 2006 Aug 10;25(35):4848-56
16547495
J Cell Physiol. 2004 Aug;200(2):213-22
15174091
Oncogene. 2004 Aug 19;23(37):6292-8
15208680
Nature. 2002 Jun 27;417(6892):949-54
12068308
Cell. 2010 Jan 22;140(2):209-21
20141835
Cell. 2004 Mar 19;116(6):855-67
15035987
Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3041-6
18287029
Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4519-24
19251651
Pigment Cell Melanoma Res. 2009 Aug;22(4):386-7
19624312
J Biol Chem. 2003 Sep 5;278(36):34548-54
12821662
Melanoma Res. 1997 Aug;7 Suppl 2:S35-42
9578415
Mol Cell Biol. 2010 Feb;30(3):806-19
19933846